jeffreyJeffrey A. Gelfand, MD, Ph.D

Dr. Jeffrey A. Gelfand, serves as a Chairman of the Scientific Advisory Board. Dr. Jeffrey A. Gelfand is a Professor and Chairman of the Department of Medicine at Tufts and Physician-in-Chief at the New England Medical center. He is currently an attending physician at Massachusetts General Hospital, a Clinical Professor at Harvard Medical School, and Professor of Medicine at Tufts. Dr. Gelfand conducts laboratory and clinical research in immunology, inflammation, infection, and tumor immunology.

  • 20 years of investment pharmaceutical R&D
  • Prior to joining TGV, Jeffrey was a Chief Scientific Officer & Founder Boston BioCom LLC, President of Pratt Medical Group
  • Over the last years, he has been increasingly active in the drug discovery and development
  • Manages the research at the M.G.H. (Massachusetts General Hospital) Research Center with an annual budget of over $600 mln
  • Jeffrey is a Clinical Professor, Department of Medicine, Harvard Medical School, member of AAAS

sushantSushant Kumar, MD, Ph.D

Dr Sushant is responsible for the management of all operational aspects and investment

  • Responsible for the management strategy and analysis
  • Over 12 years experience in healthcare research and investment management.



victortVictor Tetz, MD, Ph.D

Dr. Tetz  serves as Scientific Advisor and is responsible for the strategic planning for TGV Therapeutics. Prior to founding TGV Therapeutics, Victor successfully worked in senior positions in drug development companies.

  • Over 25 years of experience in drug discovery.
  • Senior Investigator and Group Leader in Microbiology Research for the company conducting research for Pepsi, Gen3Partners, Dole and others
  • Member of the American Society for Microbiology.

georgeGeorge Tetz, MD, Ph.D

Dr. Tetz serves as a CEO and Senior Director Clinical Development. During his career, Dr. G.Tetz has held executive positions with several biotech companies outside the US.

  • 15 years of experience in drug discovery
  • Author of over 15 patents in the field of microbiology
  • Active member of family pharmaceutical business founded in the mid-19th century
  • Prior to joining TGV, George has   worked in numerous collaborative drug discovery programs, and contributed to more than 18 novel candidates moving into clinical development.
  • In five years brought several drug candidates intended for the treatment of vaginosis, streptococcus infections, vaginal candidiasis, topical mycosis from the animal proof-of-efficacy stage to the late end points of the phase II trial (outside the US).
  • In five years Dr. G. Tetz brought a drug candidate for the treatment of acute liver injury from the animal proof-of-efficacy stage to the successful completion of Phase III trial (outside the US).